Clinical Trial Update: Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia [Phase 3]

View source ↗

Summary

A Phase 3 twelve-month safety study of eszopiclone in adults with primary insomnia has completed, summarizing its safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Lunesta (eszopiclone)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED